AFMC Decisions Regarding 2023 Resident (R-1) Match

Learners
Category
Media Releases
Similar Posts
US and Canada Remain Committed to Ensuring Medical Education Quality
September 1, 2021
The accrediting bodies for medical educational programs in the United States and Canada, and their sponsors, are committed to advancing medical education accreditation to meet the future health care needs in each of our countries. A joint Liaison Committee on Medical Education (LCME)/Committee on Accreditation of Canadian Medical Schools (CACMS) accreditation process for Canadian medical schools which was put into place eight years ago will conclude in September 2021.
AFMC Preparing to Launch MEDPREPP: A New Initiative to Support Medical Learners with Funding from the CMA Foundation
April 2, 2025

The AFMC Board of Directors has made the following decisions regarding the 2023 Resident (R-1) Match:

Interviews will continue to be in a virtual format for all, including local candidates.

The match timeline will be:

  • MSPR /transcript submission (not requiring translation) deadline: December 23, 2022
  • Application deadline: January 10, 2023
  • File Review Period: January 10 to February 6, 2023
  • Interview Period: February 6 to February 26, 2023
  • Match Day First Iteration: March 22, 2023
  • Match Day Second Iteration: April 27, 2023

We understand that shorter timelines impact all those involved in the match process and add additional pressures in an already stressed system. This timeline is a compromise between the pre-pandemic timeline and the 2021/2022 timeline.

The Deans of medicine appreciate the significant resource requirements necessary for a successful resident match in the context of a compressed timeline and commit to following up with faculty education leadership at their school to discuss the impact of the 2023 Resident (R-1) match timeline.

The AFMC Board of Directors also acknowledged the need to revisit the objectives of the final year of medical school prior to determining the 2024 Resident (R-1) match timeline.